Alkermes plc Q2 2026 Earnings Call Summary

Alkermes plc Q2 2026 Earnings Call Summary - Moby

Strategic Evolution and Operational Context

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management characterized the current period as a major phase of growth, with the orexin platform evolving from a hypersomnolence focus to a broad neurocircuitry platform for ADHD and fatigue. Alixorexton is positioned as a leading asset, being the only orexin 2 receptor agonist to demonstrate efficacy and tolerability across both NT1 and NT2 in large Phase 2 studies. The commercial strategy for LYBALVI shifted toward a long-term access model, successfully securing formulary placement with three of the largest Part D plans to cover over 80% of insured lives. VIVITROL's durability is attributed to high barriers to entry, specifically the specialized sterile manufacturing and formulation expertise required for microsphere production. The integration of Avadel and the LUMRYZ brand was described as exceeding expectations, with management noting that the team and culture have integrated seamlessly into Alkermes. Strategic positioning in sleep medicine now encompasses both oxybate and orexin mechanisms, which management believes uniquely positions the company to address the full spectrum of patient needs.

Pipeline Milestones and Strategic Outlook

Phase 3 narcolepsy program for alixorexton remains on track for expected completion in 2027., with a focus on establishing a best-in-class clinical profile. Management expects initial Phase 1b clinical data for ALKS 7290 in ADHD by the end of the third quarter of 2026, marking the first clinical evaluation of an orexin agonist in this population. The company plans to submit an sNDA for LUMRYZ in idiopathic hypersomnia by year-end 2026, targeting a potential launch as early as March 2028. Future R&D investment will be managed through a 'reinvestment' framework, where spending on new orexin indications will scale as the primary narcolepsy Phase 3 programs wind down. Management anticipates that Takeda's expected market entry will establish a 'price corridor' for the orexin class, which Alkermes will use to inform its own pricing strategy.

Risk Factors and Structural Dynamics

The company terminated its authorized generic agreement for VIVITROL with Amneal, confirming no AG will enter the market in 2027. A $26.4 million change in the fair value of contingent consideration was recorded, reflecting an increased likelihood of achieving milestones following positive LUMRYZ Phase 3 results. Gross-to-net adjustments for LYBALVI are expected to expand in the second half of 2026 due to the strategic investment in broader Part D insurance coverage. Management flagged that manufacturing revenue for RISPERDAL CONSTA has been largely realized for the year, with no meaningful contributions expected for the remainder of 2026.

Story Continues

Q&A Session Highlights

Translatability of ADHD data from adults to pediatric populations

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Management stated that adult data is highly translatable to pediatric populations through bridging PK studies, which will be addressed after dose-ranging is established in adults. The current Phase 1b study is primarily for safety and translation, utilizing EEG and behavioral markers to assess target engagement.

Regulatory pathway and endpoints for fatigue in MS and Parkinson's

The company is evaluating several established fatigue scales (MFIS, PFS-16) to align with the FDA on a primary tool for the regulatory path. The Phase 2a study for ALKS 4510 is designed to identify the signal necessary to define later-stage clinical study designs.

Potential for combination therapy using both oxybates and orexins

Management noted significant physician and patient interest in using orexins to drive daytime wakefulness alongside oxybates for nighttime sleep consolidation. Alkermes plans to generate data on combination use to support clinicians and payers, though not necessarily for initial registrational purposes.

Impact of foreign reference pricing (GLOBE/GUARD) on mid-cap biotech

CEO Richard Pops noted that while these programs could impact companies with foreign sales, Alkermes is not affected as it does not sell drugs at lower prices outside the U.S. He highlighted that such policies are particularly challenging for mid-sized companies that lack a large portfolio to offset pricing pressures.

View Comments